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General introduction and outline of this 
thesis
CHAPTER




A liver transplantation is a surgical procedure to remove a diseased liver and replace it with a 
healthy liver (or part of one) from a donor. In 1963 the first liver transplantation was performed 
by Thomas Starzl and his team in a 3-year old patient with biliary atresia.1 Unfortunately, the 
patient died during surgery because of uncontrolled bleeding. In 1967 the first successful liver 
transplantation was performed (again in a child).2 Ever since, the field of liver transplantation has 
been developing greatly. New surgical techniques, intensive perioperative care, introduction of 
immunosuppressive regimens and close collaboration in organ allocation resulted in improved 
recipient outcomes. At present, more than 50 years later, liver transplantation is the only 
curative treatment for both adults and children with end-stage liver disease, and is performed 
in over 175 centers in Europe.3
Although these developments significantly improved outcomes of children with end-stage 
liver disease, liver transplantation is still an invasive and challenging procedure. At present, two 
of the main challenges are thrombotic and bleeding complications, which both significantly 
contribute to morbidity and mortality.4-6 Incidences of hepatic artery thrombosis of 5-18% 
and 5-10% for portal vein thrombosis have been reported.7,8 Bleeding complications occur 
in 5-20%, warranting proactive hemostatic management.6 Although several risk factors for 
both thrombotic and bleeding complications have been identified, it remains unpredictable 
which individual patient will develop bleeding complications and which patients are prone to 
thrombotic complications.
Hemostasis, which is the process of blood clot formation at site of blood vessel injury to stop 
bleeding, plays a key role in the pathogenesis of these complications. The hemostatic process 
consists of platelet adhesion and aggregation, coagulation and fibrinolysis, and is regulated 
by the liver. A malfunction in the hemostatic system may lead to bleeding or thrombosis. For 
a long time, it was thought that patients with end-stage liver disease had a bleeding tendency. 
However, it now has been firmly established that adults with end-stage liver disease are in a 
state of ‘rebalanced hemostasis’.9,10 In patients with liver disease concurrent changes in both 
pro- and antihemostatic pathways occur, which affect platelet aggregation, coagulation, and 
fibrinolysis, resulting in a new hemostatic balance.11,12 This rebalanced hemostasis though, 
is fragile and can easily bend towards thrombosis or bleeding, especially during invasive 
procedures such as liver transplantation.13,14
However, children are not just little adults. Children have different liver disease etiologies, 
higher incidences of posttransplant thrombosis and a still developing hemostatic system.15,16 
Hemostasis is an evolving age-depending process that starts in utero and continues 
throughout life. Since most of the maturation of the hemostatic system occurs during 
infancy, hemostasis in children is characterized by age-related changes in the coagulation 
system, with most hemostatic proteins present in lower levels in children than in adults. More 
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knowledge of hemostasis in children undergoing liver transplantation is required to safely and 
efficiently prevent and treat both thrombotic and bleeding complications.
OUTLINE OF THIS THESIS
The aim of this thesis is to get a more rational approach to prevention and treatment of 
thrombotic and bleeding complications in pediatric patients undergoing liver transplantation. 
Therefore, we identified risk factors for thrombotic and bleeding complications, evaluated 
the current clinical antithrombotic therapy protocol, assessed hemostatic balance during 
pediatric liver transplantation and studied effects of therapeutic pro- and antihemostatic 
therapy agents. Furthermore, the consequences of vascular complications in terms of 
retransplantation were examined.
In the Netherlands, the first pediatric liver transplantation was performed in 1982. Since then, 
pediatric liver transplantation is increasingly performed, with currently 25-30 pediatric liver 
transplantations each year.17 In the Netherlands, pediatric liver transplantation is centralized in 
one center, the University Medical Center Groningen. In 2004, living donor liver transplantation 
was introduced, which presently accounts for half of the pediatric liver transplantations 
performed in the Netherlands. Chapter 2 describes a study that evaluates the outcomes of 
children who underwent a liver transplantation in the Netherlands over the past two decades.
As mentioned, the high incidence of thrombotic complications after pediatric liver 
transplantation is incompletely understood, but may be related to disease etiology, different 
plasma levels of hemostatic proteins in children and discrepancy in vessel diameters between 
donor and recipient, as well as the small diameter of hepatic vessels in children in general.18,19 
To reduce thrombotic complications, a protocol with routine antithrombotic therapy, consisting 
of unfractionated heparin followed by acetylsalicylic acid, was implemented in clinical practice. 
In Chapter 3 we aimed to evaluate incidences of thrombotic and bleeding complications 
since the implementation of routine antithrombotic therapy and to identify risk factors for 
these complications.
Since hemostasis plays a key role in the pathogenesis of thrombotic and bleeding 
complications, especially in patients with end-stage liver disease, we aimed to assess 
hemostasis in pediatric patients undergoing liver transplantation with a prospective 
cohort study, as presented in Chapter 4. Based on results in adult liver transplantation, we 
hypothesized that whereas routine laboratory tests demonstrate a hypocoagulable state, 
more advanced hemostatic tests would indicate intact or hypercoagulable hemostasis.11,20
To prevent and treat thrombotic complications, a wide variation of antithrombotic therapy is 
implemented in pediatric transplant centers worldwide.21 Yet, an evidence-base for the type of 
drug, dosing, and timing is lacking. Current anticoagulant therapy protocols and prohemostatic 
treatment strategies are usually based on experiences in pediatric cardiology or adult liver 
1
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Chapter 1
transplantation.22,23 The combination of a rebalanced hemostasis, liver transplantation, and 
the altered hemostatic state in children compared to adults makes it difficult to translate 
pro- and anticoagulant treatment regimens to pediatric liver transplantation. In Chapter 5 we 
aimed to examine the efficacy of clinically available pro- and anticoagulant drugs in pediatric 
liver transplantation. In vitro effects of different agents were tested in plasma from children 
undergoing liver transplantation, and compared the effects in children with intact liver function.
After primary liver transplantation, 11 to 15% of children develop graft failure and need to 
be retransplanted during childhood.24,26 Importantly, the main cause of graft failure are 
vascular complications, such as hepatic artery thrombosis. Outcomes after pediatric liver 
retransplantation are inferior to that of primary liver transplantation.26,28 In Chapter 6 we aimed 
to examine risk factors for pediatric liver retransplantation and develop a risk score to predict 
patient survival after pediatric liver retransplantation, and with this improve matching donor 
grafts with recipients.
Apart from thrombotic and bleeding complications, donor organ shortage forms an important 
challenge in liver transplantation, especially for children, who need a perfect size- appropriate 
graft.29 An upcoming strategy in adult liver transplantation to expand the donor pool is the use 
of preconditioned liver grafts. These preconditioned grafts are optimized and conditioned by 
using ex situ hypothermic machine perfusion, with the supplemental value of providing oxygen 
to the graft during preservation which ameliorates ischemia-reperfusion injury and offers 
better preservation of the bile ducts.30-32 So far, machine perfusion has only been reported 
in adult liver transplantation. In Chapter 7 we report the first successful transplantation of a 
pediatric liver graft after oxygenated hypothermic machine perfusion.
Finally, in Chapter 8 the results of this thesis are summarized and discussed, followed by 
future perspectives.
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